(Q35640323)

9 August 2017

1 reference

title

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies (English)

1 reference

9 August 2017

G Merlini

1

1 reference

PubMed ID

14746554

9 August 2017

P Westermark

series ordinal

2

1 reference

PubMed ID

14746554

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Journal of Internal Medicine

9 August 2017

1 reference

9 August 2017

255

1 reference

9 August 2017

2

1 reference

9 August 2017

159-178

1 reference

The characterization of soluble amyloid prepared in water

9 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Review: amyloidogenesis-unquestioned answers and unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Structural properties of an amyloid precursor of beta(2)-microglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Amyloid fibrillogenesis: themes and variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

K+ channel openers protect hippocampal neurons against oxidative injury and amyloid beta-peptide toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Transmissibility of systemic amyloidosis by a prion-like mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The origins of Alzheimer disease: a is for amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: kappa IV immunoglobulin light chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Aprotinin binding to amyloid fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Diagnostic and treatment concerns in familial Mediterranean fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Hereditary periodic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Genetic clues to understanding periodic fevers, and possible therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The premortem recognition of systemic senile amyloidosis with cardiac involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Amyloid fibril protein nomenclature -- 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The genetics of the amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Hereditary and acquired amyloid neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Inhibiting transthyretin amyloid fibril formation via protein stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Therapeutic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Secretase targets for Alzheimer's disease: identification and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Effectiveness of anthracycline against experimental prion disease in Syrian hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Anti-amyloidogenic activity of tetracyclines: studies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Nerve inflammation halts trial for Alzheimer's drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Antibody-mediated resolution of light chain-associated amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

Local synthesis of amyloid fibril precursor in AL amyloidosis of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01262.X

10.1046/J.1365-2796.2003.01262.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14746554